For a person struggling with alcohol or opioid use, the first step toward help is often the hardest. The stigma is immense, the logistics of finding a specialized provider are daunting, and the wait for an appointment can feel like an eternity. Pelago, a virtual clinic founded in 2017, is betting that same-day, nationwide access to a clinical team via a smartphone can change that equation for the better. The company, which started with a focus on tobacco cessation, has since expanded its scope to become a comprehensive telehealth provider for substance use disorders, serving a growing roster of employers and health plans who are increasingly on the hook for their members' long-term health outcomes [TechCrunch, March 2024].
The wedge of adherence in employer wellness
Pelago's core proposition is not just access, but sustained engagement. The company tackles substance use disorders across the acuity spectrum, from tobacco and cannabis to alcohol and opioids, offering cognitive behavioral therapy (CBT), live counseling, and medication-assisted treatment (MAT) through its PelagoRx program [TechCrunch, March 2024]. Its clinical model is hybrid, combining licensed physicians, nurses, and counselors with what it calls "voice-first AI apps" designed to guide users through therapeutic exercises and maintain continuity of care between live sessions. This focus on adherence is the key wedge into the employer-sponsored wellness market, where programs often suffer from low participation and high dropout rates. For a self-insured employer, improving outcomes for even a small percentage of employees with substance use challenges can translate into significant savings on downstream medical costs.
The traction metrics Pelago cites are designed to prove this wedge is working. Since its Series B round in late 2021, the company reports 11x revenue growth and 100% client retention among its enterprise customers [TechCrunch, March 2024]. Its registered user base surpassed 750,000 by August 2023, a figure that underscores both the scale of need and the company's ability to attract users through its B2B2C channel [TechCrunch, March 2024]. The customer list now includes names like MetLife, Phillips, GE Appliances, American Eagle Outfitters, and AT&T, suggesting a successful cross-industry pitch [22].
A physician-founded team with a clinical focus
The company's origins and leadership reflect its medical ambitions. Co-founder and CEO Yusuf Sherwani is an MD-trained physician, a background that informs the company's regulatory and clinical posture [TechCrunch, March 2024]. Co-founder Sarim Siddiqui serves as Chief Medical Officer, and Maroof Ahmed, another physician, is listed as a co-founder and COO [TechCrunch, March 2024] [TechCrunch, March 2020]. This clinical density at the founder level is a deliberate differentiator in a digital health category where purely technical or commercial teams can sometimes underestimate the complexities of patient care and medication management. The team has scaled to around 180 employees, with recent job postings seeking roles from clinical counselors to a creative director for growth, indicating a continued build-out of both care delivery and commercial functions [Y Combinator] [15] [16] [18].
Funding a regulated expansion
Pelago has raised a total of approximately $151 million across several rounds, providing substantial capital to navigate the capital-intensive path of a virtual clinic [TechCrunch, March 2024]. Its most recent infusion was a $58 million Series C in March 2024, following a $64 million Series B in late 2021 [TechCrunch, March 2024]. While the lead investor for the Series C remains undisclosed, the round's participants include a mix of venture firms like Atomico, Octopus Ventures, and Eight Roads, alongside strategic health investors like Startup Health [TechCrunch, March 2024].
2020 Series A | 11 | M USD
2021 Series B | 64 | M USD
2024 Series C | 58 | M USD
This capital is earmarked for user growth, clinical research, and product development. A critical, and costly, part of that development is navigating the pharmacy benefit landscape. Pelago notes it integrates with pharmacy benefit managers and wellness platforms to streamline access to prescribed medications, a non-trivial technical and commercial hurdle that is essential for a full-service MAT offering [HealthTech Alpha, N/A].
Navigating a crowded and complex field
The competitive and regulatory landscape presents clear challenges. Pelago operates in a space with several well-funded peers, each with slightly different clinical models and target markets.
| Competitor | Notable Focus / Differentiation |
|---|---|
| Bicycle Health | Specialized in opioid use disorder, strong MAT focus. |
| Workit Health | Offers care for alcohol, opioid, and stimulant use. |
| Ophelia | Telehealth for opioid use disorder, often covered by insurance. |
| Eleanor Health | Value-based care model for substance use and mental health. |
Pelago's answer to this competition is its breadth of conditions treated and its entrenched position within large employer and health plan ecosystems. The 100% client retention claim since 2021 suggests its integrated model of AI-guided CBT, counseling, and MAT is resonating with buyers who are evaluating outcomes and member satisfaction [TechCrunch, March 2024]. Furthermore, the company's rebrand from Quit Genius to Pelago in 2023 was a strategic move to signal its expanded scope beyond tobacco, aiming to own the broader "substance use management" category in the minds of enterprise purchasers [Health Podcast Network].
The risks, however, are multifaceted. The economics of telehealth for addiction treatment are still being proven at scale, with reimbursement rates and patient lifetime value under constant pressure. Clinical efficacy data, while presumably collected internally, needs broader peer-reviewed validation to satisfy skeptical payers and clinicians. Finally, the regulatory environment for prescribing controlled substances via telehealth, which was relaxed during the COVID-19 public health emergency, remains in a state of flux, introducing policy uncertainty.
The standard of care, and the road ahead
For the millions of Americans with a substance use disorder, the traditional standard of care is often a patchwork system. It might involve a primary care physician with limited time and training in addiction medicine, a referral to an outpatient clinic with a weeks-long waitlist, or an intensive inpatient program that requires taking extended leave from work and family. Adherence is fractured by these logistical barriers, and relapse is common. Pelago's bet is that a consistent, private, and immediately accessible clinical relationship, delivered digitally and supported by evidence-based tools, can create a more effective and humane pathway.
The next twelve months for Pelago will likely focus on converting its recent funding into deeper market penetration and clinical validation. Key milestones to watch include the publication of any outcomes research, the announcement of major new health plan partnerships, and the evolution of its AI tools from supportive aids to potentially more proactive clinical instruments. With a reported $27.5 million in revenue for 2024 and a team nearing 200 people, the company is now in the execution phase of its venture-scale bet. Its success will ultimately be measured not in rounds raised or users registered, but in sustained recovery rates for the patients it serves.
Sources
- [TechCrunch, March 2024] YC-backed Pelago, a virtual clinic for addiction treatment, raises $58M Series C | https://techcrunch.com/2024/03/28/yc-backed-pelago-a-virtual-clinic-for-addiction-treatment-raises-58m-series-c/
- [TechCrunch, March 2020] Quit Genius raises $11M Series A to expand into opioid, alcohol addiction treatment | https://techcrunch.com/2020/03/18/quit-genius-raises-11m-series-a-to-expand-into-opioid-alcohol-addiction-treatment/
- [HealthTech Alpha, N/A] Pelago | https://www.healthtechalpha.com/venture/pelago
- [GetLatka, 2024] How Pelago hit $27.5M revenue with a 183 person team in 2024 | https://getlatka.com/companies/pelagohealth.com
- [Y Combinator, N/A] Pelago: The world's first digital clinic for substance use management | Y Combinator | https://www.ycombinator.com/companies/pelago
- [Health Podcast Network, 2023] (Re)Meet Pelago: Well-Funded Quit Genius Rebrands | https://healthpodcastnetwork.com/episodes/startup-health-now-podcast/remeet-pelago-well-funded-quit-genius-rebrands-to-make-addiction-treatment-more-accessible/
- [11] Client mention from ZoomInfo profile | https://www.zoominfo.com/c/pelago/566160972
- [22] Client mention from Business Insider article | https://www.businessinsider.com/pitch-deck-addiction-care-startup-pelago-vc-funding-2024-3
- [15] [16] [17] [18] Job postings sourced from Greenhouse (via research snippets)